Reported about 9 hours ago
Pfizer and Merck presented mixed results in their fourth-quarter earnings, with Merck's weak guidance and oversupply issues in China contrasting Pfizer's earnings and revenue beats along with a positive 2025 outlook. Yahoo Finance's Anjalee Khemlani provided insights on the performance of these pharmaceutical stocks.
Source: YAHOO